American Journal of Medical Sciences and Medicine
ISSN (Print): 2327-6681 ISSN (Online): 2327-6657 Website: http://www.sciepub.com/journal/ajmsm Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Sciences and Medicine. 2015, 3(2), 11-13
DOI: 10.12691/ajmsm-3-2-1
Open AccessCase Report

Accuracy and Efficacy of Whole-Body 18F-FDG PET in Patient with Recurrent Colorectal Cancer: A Case Report

Mehrdad Payandeh1, Edris Sadeghi2, 3, and Masoud Sadeghi2, 3

1Department of Hematology-Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

3Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Pub. Date: April 16, 2015

Cite this paper:
Mehrdad Payandeh, Edris Sadeghi and Masoud Sadeghi. Accuracy and Efficacy of Whole-Body 18F-FDG PET in Patient with Recurrent Colorectal Cancer: A Case Report. American Journal of Medical Sciences and Medicine. 2015; 3(2):11-13. doi: 10.12691/ajmsm-3-2-1

Abstract

Background: A 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) is useful for early metabolic response assessment in various malignancies, including Colorectal Cancer (CRC). Herein, we express that Positron Emission Tomography/Computed (PET-CT) with 18FDG was very useful for early diagnosis, accuracy and additional value of whole-body in recurrent CRC. Case Report: A 50 years old woman was diagnosed with an adenocarcinoma of the left side colon. She selected for surgery with left sided hemicolectomy. Final pathologic report of adenocarcinoma high risk stage 2 patient, candidate for adjuvant chemotherapy with Folinic acid, Fluorouracil and Oxaliplatin regimen. Her carcino embryonic antigen (CEA) marker at beginning of diagnosis was in normal range but during last year of follow up her CEA marker increased and rising progressive without any complaints by patient. Gastroenterologist tried to diagnosis further secondary staging with lung, brain, abdominal and pelvic contrast computed tomography (CT) scanning but he could not find any lesion in these areas. But After second staging by whole body PET- CT that we suggested it could reveal a multiple lesion uptake in the left lateral sided of the rectum according to a stage IVB disease. For intraperitoneal metastasis adjuvant chemotherapy (CTX) with capecitabine and oxaliplatin was started. At now she is alive without significant abdominal complaint and therefore she treated with maintenance regimen CTX with capecitabine and regorafenib. Conclusion: A 18F-FDG PET/CT scan was very effective in early diagnosis and High accuracy in finding the precise location of lesion in adenocarcinoma CRC and it can prepare better survival to patients with correctly therapeutic management.

Keywords:
CRC hemicolectomy F-FDG PET/CT intraperitoneal regorafenib

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 2

References:

[1]  Gong J, Cao W, Zhang Z, Deng Y, Kang L, Zhu P, et al. Diagnostic efficacy of whole-body diffusion-weighted imaging in the detection of tumour recurrence and metastasis by comparison with 18F-2-fluoro-2-deoxyD-glucose positron emission tomography or computed tomography in patients with gastrointestinal cancer. Gastroenterol Rep (Oxf). 2014 Nov 17.
 
[2]  Ozis SE, Soydal C, Akyol C, Can N, Kucuk ON, Yagcı C, et al. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer. World J Surg Oncol. 2014 Feb 1; 12:26.
 
[3]  Yi HJ, Hong KS, Moon N, Chung SS, Lee RA, Kim KH. Reliability of F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Nodal Staging of Colorectal Cancer Patients. Ann Coloproctol 2014; 30(6): 259-265.
 
[4]  de Geus-Oei LF, Vriens D, Arens AI et al. FDGPET/CT based response-adapted treatment. Cancer Imaging 2012; 12: 324-335.
 
[5]  Payandeh M, Sadeghi M, Sadeghi E, Gholami F. Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. American Journal of Cancer Prevention, 2015; 3(1): 19-22.
 
[6]  Soydal C, Yuksel C, Kucuk NO et al. Prognostic Value of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Esophageal Cancer Patients.Mol Imaging Radionucl Ther 2014; 23: 12-15.
 
[7]  Gong J, Cao W, Zhang Z, Deng Y, Kang L, Zhu P, et al. Diagnostic efficacy of whole-body diffusion-weighted imaging in the detection of tumour recurrence and metastasis by comparison with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography or computed tomography in patients with gastrointestinal cancer. Gastroenterol Rep (Oxf). 2014 Nov 17.
 
[8]  Petersen RK, Hess S, Alavi A, Høilund-Carlsen PF. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging. 2014 Aug 15; 4(5):471-82.
 
[9]  Lee M, Yeum TS, Kim JW, Oh S, Lee SA, Moon HR, Choi YH, Han YM, Choi JM, Jang DK. Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro deoxyglucose positron emission tomography in colorectal cancer. Gut Liver. 2014 May; 8(3):254-64.
 
[10]  Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by (18)F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol. 2014 Apr 25; 48(2): 99-104.
 
[11]  Lu YY, Chen JH, Chien CR, Chen WT, Tsai SC, Lin WY, Kao CH. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis. 2013 Aug;28(8):1039-47.